Novartis has agreed to acquire biotech firm Excellergy in a deal valued at up to USD 2 billion, adding an early-stage anti-IgE therapy to its pipeline. The move strengthens its position in allergic disease treatments and signals continued investment in next-generation biologics.
Novartis has entered into an agreement to acquire privately held biotechnology company Excellergy, adding its lead experimental therapy, Exl-111, to the Swiss drugmaker’s research portfolio. The transaction, valued at up to USD 2 billion including milestone payments, is expected to close in the second half of 2026, subject to regulatory approvals, according to official disclosures.
Novartis is a global pharmaceutical company focused on innovative medicines across multiple therapeutic areas, including immunology and respiratory diseases. The acquisition is aimed at strengthening Novartis’ capabilities in immunoglobulin E (IgE)-mediated conditions, a category that includes asthma, chronic urticaria, and food allergies. Exl-111, currently in early-stage clinical development, is engineered to enhance the duration and effectiveness of IgE suppression compared to existing therapies, potentially improving treatment outcomes and dosing convenience.
This development reflects broader industry momentum toward biologics that offer differentiated mechanisms of action in chronic immune conditions. Demand for advanced allergy treatments is rising globally, particularly in developed markets where diagnosis rates and biologic adoption are higher. The deal positions Novartis to compete more directly with established and emerging players in the allergy therapeutics segment. For investors and pharmaceutical companies, the transaction highlights continued appetite for early-stage innovation despite clinical risk. It also underscores strategic prioritization of immunology pipelines, where targeted therapies can command premium pricing and long-term market share if clinical benefits are demonstrated.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.